These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36456881)

  • 1. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
    Garsed DW; Pandey A; Fereday S; Kennedy CJ; Takahashi K; Alsop K; Hamilton PT; Hendley J; Chiew YE; Traficante N; Provan P; Ariyaratne D; Au-Yeung G; Bateman NW; Bowes L; Brand A; Christie EL; Cunningham JM; Friedlander M; Grout B; Harnett P; Hung J; McCauley B; McNally O; Piskorz AM; Saner FAM; Vierkant RA; Wang C; Winham SJ; Pharoah PDP; Brenton JD; Conrads TP; Maxwell GL; Ramus SJ; Pearce CL; Pike MC; Nelson BH; Goode EL; DeFazio A; Bowtell DDL
    Nat Genet; 2022 Dec; 54(12):1853-1864. PubMed ID: 36456881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who are the long-term survivors of high grade serous ovarian cancer?
    Hoppenot C; Eckert MA; Tienda SM; Lengyel E
    Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    Res Sq; 2023 Feb; ():. PubMed ID: 36865331
    [No Abstract]   [Full Text] [Related]  

  • 6. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
    Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM
    Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
    Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
    Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
    [No Abstract]   [Full Text] [Related]  

  • 10.
    Valle BL; Rodriguez-Torres S; Kuhn E; Díaz-Montes T; Parrilla-Castellar E; Lawson FP; Folawiyo O; Ili-Gangas C; Brebi-Mieville P; Eshleman JR; Herman J; Shih IM; Sidransky D; Guerrero-Preston R
    Cancer Prev Res (Phila); 2020 Sep; 13(9):783-794. PubMed ID: 32581010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.
    Ferri-Borgogno S; Zhu Y; Sheng J; Burks JK; Gomez JA; Wong KK; Wong STC; Mok SC
    Cancer Res; 2023 May; 83(9):1503-1516. PubMed ID: 36787106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Cheng Z; Mirza H; Ennis DP; Smith P; Morrill Gavarró L; Sokota C; Giannone G; Goranova T; Bradley T; Piskorz A; Lockley M; ; Kaur B; Singh N; Tookman LA; Krell J; McDermott J; Macintyre G; Markowetz F; Brenton JD; McNeish IA
    Clin Cancer Res; 2022 Jul; 28(13):2911-2922. PubMed ID: 35398881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Integrative Genomic Analysis of Formalin Fixed Paraffin-Embedded Archived Serous Ovarian Carcinoma Comparing Long-term and Short-term Survivors.
    Stålberg K; Crona J; Razmara M; Taslica D; Skogseid B; Stålberg P
    Int J Gynecol Cancer; 2016 Jul; 26(6):1027-32. PubMed ID: 27177282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
    Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
    Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
    Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
    J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.